These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1118 related items for PubMed ID: 21939718

  • 21. Protection against influenza virus infection by intranasal administration of hemagglutinin vaccine with chitin microparticles as an adjuvant.
    Hasegawa H, Ichinohe T, Strong P, Watanabe I, Ito S, Tamura S, Takahashi H, Sawa H, Chiba J, Kurata T, Sata T.
    J Med Virol; 2005 Jan; 75(1):130-6. PubMed ID: 15543590
    [Abstract] [Full Text] [Related]

  • 22. Diphtheria toxoid loaded poly-(epsilon-caprolactone) nanoparticles as mucosal vaccine delivery systems.
    Singh J, Pandit S, Bramwell VW, Alpar HO.
    Methods; 2006 Feb; 38(2):96-105. PubMed ID: 16442811
    [Abstract] [Full Text] [Related]

  • 23. Rabbit nasal immunization against influenza by dry-powder form of chitosan nanospheres encapsulated with influenza whole virus and adjuvants.
    Dehghan S, Tafaghodi M, Bolourieh T, Mazaheri V, Torabi A, Abnous K, Tavassoti Kheiri M.
    Int J Pharm; 2014 Nov 20; 475(1-2):1-8. PubMed ID: 25148732
    [Abstract] [Full Text] [Related]

  • 24. The Eurocine L3 adjuvants with subunit influenza antigens induce protective immunity in mice after intranasal vaccination.
    Petersson P, Hedenskog M, Alves D, Brytting M, Schröder U, Linde A, Lundkvist A.
    Vaccine; 2010 Sep 07; 28(39):6491-7. PubMed ID: 20637767
    [Abstract] [Full Text] [Related]

  • 25. Relationship between structure and adjuvanticity of N,N,N-trimethyl chitosan (TMC) structural variants in a nasal influenza vaccine.
    Hagenaars N, Verheul RJ, Mooren I, de Jong PH, Mastrobattista E, Glansbeek HL, Heldens JG, van den Bosch H, Hennink WE, Jiskoot W.
    J Control Release; 2009 Dec 03; 140(2):126-33. PubMed ID: 19712713
    [Abstract] [Full Text] [Related]

  • 26. Alkyl polyglycoside, a highly promising adjuvant in intranasal split influenza vaccines.
    Wu H, Bao Y, Wang X, Zhou D, Wu W.
    Hum Vaccin Immunother; 2017 Jun 03; 13(6):1-9. PubMed ID: 28129034
    [Abstract] [Full Text] [Related]

  • 27. Intranasal interleukin-12 is a powerful adjuvant for protective mucosal immunity.
    Arulanandam BP, O'Toole M, Metzger DW.
    J Infect Dis; 1999 Oct 03; 180(4):940-9. PubMed ID: 10479116
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.
    Bright RA, Carter DM, Daniluk S, Toapanta FR, Ahmad A, Gavrilov V, Massare M, Pushko P, Mytle N, Rowe T, Smith G, Ross TM.
    Vaccine; 2007 May 10; 25(19):3871-8. PubMed ID: 17337102
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Nasal vaccination with r4M2e.HSP70c antigen encapsulated into N-trimethyl chitosan (TMC) nanoparticulate systems: Preparation and immunogenicity in a mouse model.
    Dabaghian M, Latifi AM, Tebianian M, NajmiNejad H, Ebrahimi SM.
    Vaccine; 2018 May 11; 36(20):2886-2895. PubMed ID: 29627234
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection.
    Ichinohe T, Watanabe I, Ito S, Fujii H, Moriyama M, Tamura S, Takahashi H, Sawa H, Chiba J, Kurata T, Sata T, Hasegawa H.
    J Virol; 2005 Mar 11; 79(5):2910-9. PubMed ID: 15709010
    [Abstract] [Full Text] [Related]

  • 34. Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery.
    Sayin B, Somavarapu S, Li XW, Thanou M, Sesardic D, Alpar HO, Senel S.
    Int J Pharm; 2008 Nov 03; 363(1-2):139-48. PubMed ID: 18662762
    [Abstract] [Full Text] [Related]

  • 35. Intranasal c-di-GMP-adjuvanted plant-derived H5 influenza vaccine induces multifunctional Th1 CD4+ cells and strong mucosal and systemic antibody responses in mice.
    Madhun AS, Haaheim LR, Nøstbakken JK, Ebensen T, Chichester J, Yusibov V, Guzman CA, Cox RJ.
    Vaccine; 2011 Jul 12; 29(31):4973-82. PubMed ID: 21600260
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Induction of Local Secretory IgA and Multifunctional CD4⁺ T-helper Cells Following Intranasal Immunization with a H5N1 Whole Inactivated Influenza Virus Vaccine in BALB/c Mice.
    Trondsen M, Aqrawi LA, Zhou F, Pedersen G, Trieu MC, Zhou P, Cox RJ.
    Scand J Immunol; 2015 May 12; 81(5):305-17. PubMed ID: 25737202
    [Abstract] [Full Text] [Related]

  • 39. Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model.
    Hagenaars N, Mastrobattista E, Glansbeek H, Heldens J, van den Bosch H, Schijns V, Betbeder D, Vromans H, Jiskoot W.
    Vaccine; 2008 Dec 02; 26(51):6555-63. PubMed ID: 18848856
    [Abstract] [Full Text] [Related]

  • 40. Poly(I:C) augments inactivated influenza virus-chitosan nanovaccine induced cell mediated immune response in pigs vaccinated intranasally.
    Renu S, Feliciano-Ruiz N, Ghimire S, Han Y, Schrock J, Dhakal S, Patil V, Krakowka S, Renukaradhya GJ.
    Vet Microbiol; 2020 Mar 02; 242():108611. PubMed ID: 32122615
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 56.